Business Context and Reporting Period
This Form 8-K Current Report was filed by ImmuCell Corporation (Nasdaq: ICCC) on February 2, 2026, covering events occurring on January 27, 2026. The filing details the entry into material definitive agreements regarding executive compensation and the appointment of certain officers.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation structures and equity grants.
Material Changes and Executive Compensation
Effective January 27, 2026, the Company entered into new employment agreements and issued equity grants to key executives:
- Timothy C. Fiori (CFO):
- Annual Base Salary: $315,000.
- Target Cash Bonus: 50% of base salary (up to 60% if targets exceeded by 20%), effective for fiscal year ending December 31, 2026.
- Stock Option Grant: 120,000 shares under the 2025 Plan.
- Bobbi Jo Brockmann (SVP Sales and Marketing):
- Annual Base Salary: $300,000.
- Target Cash Bonus: 50% of base salary (up to 60% if targets exceeded by 20%), effective for fiscal year ending December 31, 2026.
- Stock Option Grant: 100,000 shares under the 2025 Plan.
- Olivier te Boekhorst (CEO):
- Received a performance-based stock option grant for 110,000 shares under the 2025 Plan.
- Vesting Condition: Net operating income for four consecutive calendar quarters must equal or exceed 300% of the audited net operating income for the 2025 fiscal year.
Common Terms for Options: All grants have an exercise price of $6.26 per share and expire 10 years from the grant date. Options for Mr. Fiori and Ms. Brockmann vest in three equal annual installments starting January 2027. All grants are subject to acceleration upon a change of control or certain terminations.
Guidance, Outlook, and Risks
The filing does not provide forward-looking financial guidance or general business outlook. However, it establishes specific performance targets for 2026 executive bonuses and the CEO's equity vesting, which are tied to achieving preset financial and strategic goals. Risks associated with these agreements include the potential for retroactive clawback of cash bonuses if mandated by company policy or applicable laws.
Investor Verification Checklist
- Verify the Company's audited net operating income for fiscal year 2025 to assess the feasibility of the CEO's performance-based vesting condition (300% threshold).
- Review the full text of Exhibits 10.1, 10.2, and 10.3 for specific qualitative targets and clawback provisions not detailed in the summary.
- Confirm the dilution impact of the 330,000 total shares granted in options on the current share count.
- Monitor the Company's ability to meet the 2026 financial targets required for the 50-60% cash bonuses for the CFO and SVP.